01511nam a2200265   4500001000800000005001700008007000300025008004100028040000800069041000800077100004000085245006200125300002500187520066400212650002900876650002800905650002500933650002400958650004300982650003201025700003001057773011001087942003101197999001701228ESSALUD20260902150847.0ta      t        pe ||||| |||| 00| 0 spa d  aBMG  aeng  aSpyropoulos, Alex C. eAutor954428  aAdvanced Therapy for Intermediate-Risk Pulmonary Embolism  apáginas: 2052-2054  aPulmonary embolism is the third leading cardiovascular cause of complications and death after myocardial infarction and stroke, with a rising incidence globally. The approach to management of acute pulmonary embolism as a condition to be treated nonsurgically with systemic heparin anticoagulation was established more than 60 years ago. Patients with high-risk pulmonary embolism and cardiogenic shock appear to benefit from early thrombus removal, with rapid reductions in pulmonary obstruction and pulmonary vascular resistance from baseline and a lower risk of death than with anticoagulation alone, but at the cost of a nearly 10% risk of major bleeding.  aANTICOAGULACIÓN953834  aTROMBOEMBOLISMO 932218  aCARDIOLOGÍA911301  aNEUMOLOGÍA925628  aMEDICINA CLÍNICA HOSPITALARIA953754  aRADIOLOGÍA GENERAL954381  aVedantham, Suresh 9538960 022717922665dMassachusetts NEJM GroupoNEJM013tThe New England Journal of Medicine wESSALUDx0028-4793  cARTICULOSe2026-08-28zsqb  c22891d22891